Quick Answer
Indaptus Therapeutics, Inc. reported Stockholders Equity of $3.15 million for fiscal year 2025.
Indaptus Therapeutics, Inc. Stockholders Equity — Annual History
| Fiscal Year | Stockholders Equity | YoY Change |
|---|---|---|
| 2025 | $3.15M | -20.1% |
| 2024 | $3.94M | -67.3% |
| 2023 | $12.08M | -51.0% |
| 2022 | $24.63M | -31.4% |
| 2021 | $35.90M | +15202.8% |
| 2020 | -$237.7K | -107.4% |
| 2019 | $3.21M | — |
Quarterly Stockholders Equity
| Quarter Ending | Stockholders Equity | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | $4.61M | -23.3% | +375.2% |
| June 30, 2025 | -$1.67M | -127.1% | -159.8% |
| March 31, 2025 | $2.80M | -70.1% | -29.0% |
| December 31, 2024 | $3.94M | -67.3% | -34.3% |
| September 30, 2024 | $6.00M | -60.8% | -2.6% |
| June 30, 2024 | $6.17M | -66.9% | -34.1% |
| March 31, 2024 | $9.36M | -55.8% | -22.5% |
| December 31, 2023 | $12.08M | -51.0% | -21.2% |
- Indaptus Therapeutics, Inc. showed a decrease of -20.1% in Stockholders Equity compared to the prior fiscal year.
- Over the 2019–2025 period, Indaptus Therapeutics, Inc.’s stockholders equity has declined by 1.8% (from $3.21 million to $3.15 million).
- The most recent figure is from Indaptus Therapeutics, Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 17, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: